Equities research analysts forecast that CareDx Inc (NASDAQ:CDNA) will report earnings per share (EPS) of ($0.13) for the current quarter, according to Zacks. Two analysts have provided estimates for CareDx’s earnings. The lowest EPS estimate is ($0.15) and the highest is ($0.11). CareDx also posted earnings of ($0.13) per share during the same quarter last year. The business is scheduled to announce its next quarterly earnings results after the market closes on Thursday, March 22nd.
Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover CareDx.
CDNA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of CareDx in a research report on Wednesday, January 31st. Zacks Investment Research upgraded CareDx from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research report on Wednesday, January 10th. Finally, ValuEngine upgraded CareDx from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $8.65.
Shares of CareDx (NASDAQ:CDNA) traded up $0.13 on Monday, reaching $5.87. The company had a trading volume of 81,417 shares, compared to its average volume of 197,240. The company has a market capitalization of $164.18, a P/E ratio of -3.28 and a beta of 0.72. CareDx has a 12 month low of $0.76 and a 12 month high of $7.98. The company has a debt-to-equity ratio of -124.53, a quick ratio of 0.35 and a current ratio of 0.55.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/12/analysts-anticipate-caredx-inc-cdna-will-post-earnings-of-0-13-per-share.html.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.